Drugs / Gemlapodect
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06315751 | Sep 2024 → Jun 2026 overdue | Tourette syndrome | Noema Pharma AG | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05583955 | Jul 2022 → Oct 2023 | stutter disorder | Noema Pharma AG | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-10-17 | Noema Pharma AG | Results Noema Pharma Announces NOE-105 (gemlapodect) Phase 2a Study in Tourette Syndrome met Primary and all Key Secondary Endpoints noemapharma.com ↗ |
| 2022-06-27 | Noema Pharma AG | Regulatory Noema Pharma announces FDA Investigational New Drug (IND) Authorization for Orpheus Phase 2b study of PDE10A inhibitor gemlapodect (NOE-105) in Childhood Onset Fluency Disorder noemapharma.com ↗
We are very pleased to announce an additional IND authorization, which reflects the dedication and efficiency of our clinical development team, |
All press releases naming this drug 5 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gemlapodect | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06315751 ↗ |
| Known as | NOE-105 | “This study is designed to evaluate the efficacy and safety of gemlapodect (NOE-105) on reducing tics associated with Tourette Syndrome (TS) in adults with TS.” NCT06315751 ↗ |
| Action | Inhibit | “NOE-105 is an investigational selective PDE10A inhibitor with a potential therapeutic effect for the treatment of COFD.” NCT05583955 ↗ |
| Modality | Small molecule | — CHEMBL5314465 ↗ |
| Route | Oral | “Administered in the form of oral capsules.” NCT06315751 ↗ |
| Target | PDE10A | “NOE-105 is an investigational selective PDE10A inhibitor with a potential therapeutic effect for the treatment of COFD.” NCT05583955 ↗ |